Study record · Mazdutide
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1)
At week 48: -11.00% (4 mg), -14.01% (6 mg), +0.30% placebo; ≥15% loss in 35.7%, 49.5%, 2.0%.
Key result
At week 48: -11.00% (4 mg), -14.01% (6 mg), +0.30% placebo; ≥15% loss in 35.7%, 49.5%, 2.0%.
Study details
Study designRandomized, double-blind, placebo-controlled trial
PhasePhase 3
PopulationChinese adults with overweight or obesity
Sample size610
RouteSubcutaneous
Regimen / exposure4 mg or 6 mg once weekly
Duration48 weeks
ComparatorPlacebo
Primary endpoint / questionPercent body-weight change
Safety resultGI events most common and mostly mild-moderate; discontinuation 1.5%, 0.5%, 1.0%.
Key limitationsSingle-country population; cross-trial comparisons with other incretins are indirect.
Registry / identifierNCT05607680